{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T01:50:18Z","timestamp":1746237018299},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>There are many trials on the combination of Pinaverium bromide (PB) and Flupentixol-melitracen (FM) in the treatment of diarrhea-type irritable bowel syndrome (IBS-D), but the sample sizes are small, and the research conclusions are inconsistent. Thus, a meta-analysis was performed, aiming to evaluate the efficacy and safety of this combination therapy in patients with IBS-D.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A systematic literature search was conducted in 7 databases covering the period up to July 2018 to identify randomized controlled trials (RCTs) of PB combined with FM versus PB alone for IBS-D. The primary outcome was the total symptom relief rate. The other outcomes were the adverse events rate, HAMA\/SAS score, and HAMD\/SDS score. The methodological quality of the RCTs was assessed independently using 6 criteria according to the Cochrane Collaboration. All data were analyzed using Review Manager 5.3.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Fifteen RCTs with 1487 participants were identified from 2005 to 2018. Compared with PB alone, 15 RCTs showed significant effects of PB plus FM in terms of improved symptom relief in patients with IBS-D (n\u200a=\u200a1487, OR\u200a=\u200a5.17, 95%CI, 3.79\u20137.07, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.00001). Eleven RCTs reported adverse effects in both the PB plus FM and PB groups, there was no statistically significant difference in the adverse events rate between the 2 groups (n\u200a=\u200a1207, OR\u200a=\u200a2.91, 95%CI, 0.91\u20139.28, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.07). Two RCTs and 3 RCTs reported HAMA and HAMD scores respectively, and 3 RCTs reported both SAS and SDS scores. After treatment, the above scores in the PB plus FM group were significantly lower than the PB group (all <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.01). However, the trials were deemed to have a medium risk of bias.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The efficacy of PB combined with FM is superior to PB alone in the treatment of IBS-D, and it is safe for clinical use. However, the conclusions still need to be verified by conducting more large-scale and high-quality RCTs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000014064","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T13:07:26Z","timestamp":1548335246000},"page":"e14064","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of pinaverium bromide combined with flupentixol-melitracen for diarrhea-type irritable bowel syndrome"],"prefix":"10.1097","volume":"98","author":[{"given":"Lifeng","family":"Qin","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, First Affiliated Hospital of Guangxi Medical University"},{"name":"Department of infectious diseases, First Affiliated Hospital of Guangxi Medical University, Nanning, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinmei","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of infectious diseases, First Affiliated Hospital of Guangxi Medical University, Nanning, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of infectious diseases, First Affiliated Hospital of Guangxi Medical University, Nanning, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, First Affiliated Hospital of Guangxi Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of infectious diseases, First Affiliated Hospital of Guangxi Medical University, Nanning, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230928","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1440-1746.2010.06353.x","article-title":"Asian consensus on irritable bowel syndrome","volume":"25","author":"Gwee","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"R2-20230928","first-page":"146","article-title":"Epidemiology of irritable bowel syndrome in the former communist countries from Eastern Europe: a systematic review","volume":"88","author":"Rusu","year":"2015","journal-title":"Clujul Med"},{"key":"R3-20230928","first-page":"71","article-title":"The epidemiology of irritable bowel syndrome","volume":"2014","author":"Canavan","year":"2014","journal-title":"Clin Epidemiol"},{"key":"R4-20230928","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis","volume":"10","author":"Lovell","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R5-20230928","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5009\/gnl.2011.5.1.29","article-title":"Anxiety, depression and quality of life in patients with irritable bowel syndrome","volume":"5","author":"Cho","year":"2011","journal-title":"Gut Liver"},{"issue":"(Suppl 2)","key":"R6-20230928","first-page":"II1","article-title":"The functional gastrointestinal disorders and the Rome II process","volume":"45","author":"Drossman","year":"1999","journal-title":"Gastroenterology"},{"key":"R7-20230928","first-page":"237","article-title":"Rome III: new standard for functional gastrointestinal disorders","volume":"15","author":"Drossman","year":"2006","journal-title":"J Gastrointestin Liver Dis"},{"key":"R9-20230928","first-page":"1166","article-title":"Clinical observation of deanxit combined with pinaverium bromide in irritable bowel syndrome","volume":"26","author":"Huang","year":"2005","journal-title":"J Qiqihar Med Coll"},{"key":"R10-20230928","first-page":"1","article-title":"Observation of effects of small-dose deanxit combining pinaverium bromide for irritable bowel syndrome","volume":"27","author":"Huang","year":"2009","journal-title":"China Foreign Med Treat"},{"key":"R11-20230928","first-page":"11","article-title":"The analysis of pinaverium bromide combined with deanxit in the treatment of 120 case of irritable bowel syndrome","volume":"6","author":"Yan","year":"2009","journal-title":"China Med Herald"},{"key":"R12-20230928","first-page":"48","article-title":"Efficacy observation of deanxit combined with pinaverium bromide in irritable bowel syndrome","volume":"22","author":"Li","year":"2010","journal-title":"Chin J Clin Gastroenterol"},{"key":"R13-20230928","first-page":"3717","article-title":"Clinical analysis of deanxit combined with dicetel in irritable bowel syndrome","volume":"16","author":"Li","year":"2012","journal-title":"Public Med Forum Mag"},{"key":"R14-20230928","first-page":"12","article-title":"Investigate deanxit combined with pinaverium bromide in the treatment of older patients with irritable bowel syndrome","volume":"21","author":"Meng","year":"2012","journal-title":"China Foreign Med Treat"},{"key":"R15-20230928","first-page":"19","article-title":"Efficacy of deanxit in irritable bowel syndrome","volume":"9","author":"Zhang","year":"2012","journal-title":"J North Pharm"},{"key":"R16-20230928","first-page":"105","article-title":"Efficacy of deanxit combined with pinaverium bromide in irritable bowel syndrome","volume":"7","author":"Qin","year":"2013","journal-title":"Chin J Modern Drug Appl"},{"key":"R17-20230928","first-page":"11","article-title":"Small-dose deanxit combined with pinaverium bromide in irritable bowel syndrome","volume":"8","author":"Zhu","year":"2013","journal-title":"China Pract Med"},{"key":"R18-20230928","first-page":"86","article-title":"Efficacy of flupentixol and melitracen combined with pinaverium bromide inirritable bowel syndrome","volume":"36","author":"Chen","year":"2016","journal-title":"Chin J Biochem Pharm"},{"key":"R19-20230928","first-page":"82","article-title":"Flupenthixol melitracen combined with pinaverium bromide in the long course treatment of diarrheic irritable bowel syndrome in 74 cases","volume":"25","author":"Ni","year":"2016","journal-title":"China Pharm"},{"key":"R20-20230928","first-page":"113","article-title":"Efficacy analysis of deanxit combined with Pinaverium bromide in irritable bowel syndrome","volume":"10","author":"Shi","year":"2016","journal-title":"Chin J Modern Drug Appl"},{"key":"R21-20230928","first-page":"54","article-title":"Clinical observation of flupentixol and melitracen combined with pinaverium bromide in the treatment of irritable bowel syndrome","volume":"37","author":"Deng","year":"2017","journal-title":"Clin Med"},{"key":"R22-20230928","first-page":"172","article-title":"Clinical efficacy of flupentixol and melitracen combined with pivalvonium in irritable bowel syndrome","volume":"27","author":"Lin","year":"2017","journal-title":"China Health Care Nutr"},{"key":"R23-20230928","first-page":"223","article-title":"The effect of pinaverium bromide combined with flupentixol and melitracen in the treatment of irritable bowel syndrome with depression and anxiety","volume":"8","author":"Peng","year":"2018","journal-title":"China Med Pharm"},{"key":"R24-20230928","doi-asserted-by":"crossref","first-page":"306","DOI":"10.5217\/ir.2015.13.4.306","article-title":"Pharmacologic Agents for Chronic Diarrhea","volume":"13","author":"Lee","year":"2015","journal-title":"Intest Res"},{"key":"R25-20230928","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/gut.2004.048884","article-title":"Use of psychopharmacological agents for functional gastrointestinal disorders","volume":"54","author":"Clouse","year":"2005","journal-title":"Gut"},{"key":"R27-20230928","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2174\/1570159X14666160324144154","article-title":"Pathogenesis, experimental models and contemporary pharmacotherapy of irritable bowel syndrome: story about the brain-gut axis","volume":"14","author":"Tsang","year":"2016","journal-title":"Curr Neuropharmacol"},{"key":"R28-20230928","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5056\/jnm.2011.17.2.131","article-title":"Biopsychosocial model of irritable bowel syndrome","volume":"17","author":"Tanaka","year":"2011","journal-title":"J Neurogastroenterol Motil"},{"key":"R29-20230928","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1152\/ajpgi.2001.280.4.G519","article-title":"Stress and irritable bowel syndrome","volume":"280","author":"Mayer","year":"2001","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R30-20230928","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/nrgastro.2013.10","article-title":"The role of psychosocial factors and psychiatric disorders in functional dyspepsia","volume":"10","author":"Van","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R31-20230928","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.3748\/wjg.v21.i15.4652","article-title":"Effect of clinician-patient communication on compliance with flupentixol-melitracen in functional dyspepsia patients","volume":"21","author":"Yan","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R32-20230928","doi-asserted-by":"crossref","first-page":"733","DOI":"10.11569\/wcjd.v17.i7.733","article-title":"Treatment of diarrhea-predominant Post-infectious irritable bowel syndrome with Deanxit: An analysis of 30 cases","volume":"17","author":"Chen","year":"2009","journal-title":"World Chin J Digestol"},{"key":"R33-20230928","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/j.1365-2036.2008.03677.x","article-title":"Clinical trial: a randomized controlled cross-over study of flupenthixol+melitracen in functional dyspepsia","volume":"27","author":"Hashash","year":"2008","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201901110-00059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T03:19:33Z","timestamp":1695871173000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201901110-00059"}},"subtitle":["A systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014064","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}